Editorial: anti-tumour necrosis factor antibodies - can efficacy be regained?

被引：1
作者：
Bar-Yoseph, H. [1 ]
Chowers, Y. [1 ]
机构：
[1] Rambam Hlth Care Campus, Gastroenterol Inst, Haifa, Israel
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2017年 / 45卷 / 11期
关键词：
INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB; IMMUNOMODULATOR; THIOPURINES; THERAPY;
D O I：
10.1111/apt.14047
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1473 / 1474
页数：2
相关论文
共 12 条
  • [11] Pathogenic Long-Lived Plasma Cells and Their Survival Niches in Autoimmunity, Malignancy, and Allergy
    Winter, Oliver
    Dame, Christof
    Jundt, Franziska
    Hiepe, Falk
    [J]. JOURNAL OF IMMUNOLOGY, 2012, 189 (11) : 5105 - 5111
  • [12] Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy
    Yarur, Andres J.
    Kubiliun, Maddie J.
    Czul, Frank
    Sussman, Daniel A.
    Quintero, Maria A.
    Jain, Anjali
    Drake, Katherine A.
    Hauenstein, Scott I.
    Lockton, Steven
    Deshpande, Amar R.
    Barkin, Jamie S.
    Singh, Sharat
    Abreu, Maria T.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (06) : 1118 - +
12